0000950142-20-002633.txt : 20201127 0000950142-20-002633.hdr.sgml : 20201127 20201127090838 ACCESSION NUMBER: 0000950142-20-002633 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20201127 DATE AS OF CHANGE: 20201127 EFFECTIVENESS DATE: 20201127 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000792977 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042742593 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-10865 FILM NUMBER: 201352919 BUSINESS ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 6174983300 MAIL ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: AMAG PHARMACEUTICALS INC. DATE OF NAME CHANGE: 20070724 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MAGNETICS INC DATE OF NAME CHANGE: 19920703 15-12B 1 eh200115727_1512b.htm FORM 15-12B
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 15
 
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR
SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934.
  
Commission File Number:     
001-10865
 

AMAG PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
1100 Winter Street,
Waltham, Massachusetts, 02451
(425) 943-8000
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
 
Common Stock, par value $0.01 per share
(Title of each class of securities covered by this Form)
 
None
(Titles of all other classes of securities for which
a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
 
 
Rule 12g-4(a)(1) 
☒
 
Rule 12g-4(a)(2) 
☐
 
Rule 12h-3(b)(1)(i) 
☒
 
Rule 12h-3(b)(1)(ii) 
☐
 
Rule 15d-6 
☐
 
Rule 15d-22(b)
☐
 
Approximate number of holders of record as of the certification or notice date:    1       
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, AMAG Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: November 27, 2020
AMAG PHARMACEUTICALS, INC.
  
       

By: 
 /s/ Michael Porter  
 
Name:
Michael Porter
  
 
Title:
President and Chief Executive Officer